Earnings call transcript: Zepp Health’s Q4 2025 revenue surges 43% By Investing.com

Zepp Health reported Q4 2025 revenue of $85.2M, up 43% YoY, with a record gross margin of 40.4% and a reduced net loss of $6.4M (improved ~71.6% YoY); aftermarket stock was up 1.17% to $20.59. Management guided Q1 2026 revenue of $50–$55M (~30–40% YoY growth), highlighted premiumization and new product launches (T-Rex Ultra 2, Active Max, Active 3 Premium) and said operating cash flow was positive. Key risks include memory chip cost inflation, supply-chain constraints (inventory buildup noted), FX and ongoing net losses despite improvement. Overall outlook is constructive but watch execution on supply and margin sustainability.

Analysis

Zepp’s strategic premiumization and ecosystem push create an asymmetric payoff: higher ASPs and differentiated software features lift per-user economics, which should compound LTV faster than unit growth. That makes the company less dependent on volume-driven promotional cycles, but it also shifts the battleground to supply, premium component sourcing, and brand credibility—areas where second‑order effects (athlete endorsements, HYROX integrations) materially lower customer acquisition cost and raise retention if executed cleanly.

The principal medium-term risk is execution on supply and inventory management. Strategic “risk buys” of components can protect sell‑through but tie up working capital and increase obsolescence risk if product cycles accelerate; meanwhile, constrained suppliers will prioritize large OEMs in a memory/commodity squeeze, creating a timing mismatch between demand and margin realization. Near-term catalysts to watch are sell‑through trends for the new high‑end SKUs, any sequential improvement in gross margin mix, and updates to buyback cadence—these will move the stock within weeks to months.

The consensus is underweighting the optionality in a software+hardware flywheel: if Zepp converts a modest percentage of free device users to higher‑margin subscription or paid features, valuation re‑rating could be quick and non‑linear. The counterpoint is that premiumization is reversible; aggressive promotional responses from larger incumbents or a sudden spike in component costs would compress margins and force a return to volume tactics, reversing the thesis within quarters.

Key Decisions for Investors

• Long ZEPP (equity): build a 2–3% portfolio position with a 6–12 month horizon. Rationale: asymmetric upside from continued ASP/mix improvement and capital returns; set a disciplined stop-loss at 25–30% and take-profit bands at +40% and +60% to capture a re‑rating while limiting downside.
• Long ZEPP calls (options): buy 12–18 month LEAPs roughly 25–35% delta sized at 25–50% of the equivalent equity exposure to maximize upside (defined premium risk). Target 3x+ return if premiumization accelerates; loss limited to paid premium if execution disappoints.
• Relative (pair) trade — Long ZEPP / Short 1810.HK (Xiaomi) equal notional, 6–12 month horizon: isolates a premiumization/ASP rotation theme versus exposure to mass‑market, low‑margin wearable competition. Reward if Zepp sustains higher gross margins and Xiaomi faces cyclical pressure from inventory/price competition; risk if broader cyclical consumer demand weakens.
• Tail hedge: buy a short‑dated (3–6 month) put spread on ZEPP sized to protect 25–35% of the equity position if you hold through upcoming reporting and supply updates. Cost‑effective downside insurance if component cost shocks or promotional responses materialize.